LAGUNA HILLS, CA, May 6, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that advances have been completed in the manufacturing process for the clinical trial product that will be
Read more →LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has added a new CEO interview to the company’s website. Chief Executive Officer, Kenneth L. Waggoner, was
Read more →LAGUNA HILLS, CA, January 17, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its Chief Executive Officer, Kenneth L. Waggoner, will be featured in a live interview on “The Big
Read more →LAGUNA HILLS, CA, January 15, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced PharmaCyte’s partner, Austrianova, has successfully encapsulated the live cells used in PharmaCyte’s therapy for its planned clinical
Read more →LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released an interview with Lyon Gleich, M.D., of Medpace, a global full-service clinical contract research organization (CRO). Dr. Gleich serves as the Medical Monitor and key team
Read more →LAGUNA HILLS, CA, December 4, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has engaged cGMP Validation L.L.C. (cGMP Validation) to assist in the preparation of the Investigational
Read more →LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has selected Medpace, Inc. as the Contract Research Organization (CRO) to conduct PharmaCyte’s clinical trial in
Read more →LAGUNA HILLS, CA, October 30, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Patent Application titled “Encapsulated Cells Producing Cytochrome P450 and Methods of Use Thereof,”
Read more →LAGUNA HILLS, CA, October 9, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its PCT patent application covering a targeted therapy
Read more →LAGUNA HILLS, CA, October 1, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully determined the modified site and chromosome location of the cytochrome P450-2B1
Read more →